AKOYA BIOSCIENCES INC (AKYA)

US00974H1041 - Common Stock

2.45  -0.04 (-1.61%)

Fundamental Rating

2

AKYA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. AKYA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AKYA is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

AKYA had negative earnings in the past year.
In the past year AKYA has reported a negative cash flow from operations.
In the past 5 years AKYA always reported negative net income.
In the past 5 years AKYA always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -44.60%, AKYA is doing worse than 82.46% of the companies in the same industry.
AKYA's Return On Equity of -425.20% is on the low side compared to the rest of the industry. AKYA is outperformed by 91.23% of its industry peers.
Industry RankSector Rank
ROA -44.6%
ROE -425.2%
ROIC N/A
ROA(3y)-32.83%
ROA(5y)-29.39%
ROE(3y)-91.62%
ROE(5y)-89.72%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

AKYA's Gross Margin of 57.72% is fine compared to the rest of the industry. AKYA outperforms 77.19% of its industry peers.
In the last couple of years the Gross Margin of AKYA has declined.
AKYA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.54%
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

AKYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
AKYA has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, AKYA has a worse debt to assets ratio.

2.2 Solvency

AKYA has an Altman-Z score of -2.36. This is a bad value and indicates that AKYA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.36, AKYA is doing worse than 87.72% of the companies in the same industry.
AKYA has a Debt/Equity ratio of 5.62. This is a high value indicating a heavy dependency on external financing.
AKYA has a worse Debt to Equity ratio (5.62) than 92.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.62
Debt/FCF N/A
Altman-Z -2.36
ROIC/WACCN/A
WACC12.22%

2.3 Liquidity

A Current Ratio of 2.75 indicates that AKYA has no problem at all paying its short term obligations.
AKYA has a Current ratio (2.75) which is comparable to the rest of the industry.
AKYA has a Quick Ratio of 1.85. This is a normal value and indicates that AKYA is financially healthy and should not expect problems in meeting its short term obligations.
AKYA's Quick ratio of 1.85 is in line compared to the rest of the industry. AKYA outperforms 42.11% of its industry peers.
Industry RankSector Rank
Current Ratio 2.75
Quick Ratio 1.85

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.99% over the past year.
Looking at the last year, AKYA shows a decrease in Revenue. The Revenue has decreased by -4.99% in the last year.
The Revenue has been growing by 31.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)30.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.23%
Revenue 1Y (TTM)-4.99%
Revenue growth 3Y31.56%
Revenue growth 5YN/A
Sales Q2Q%-25.12%

3.2 Future

The Earnings Per Share is expected to grow by 11.66% on average over the next years. This is quite good.
Based on estimates for the next years, AKYA will show a small growth in Revenue. The Revenue will grow by 4.60% on average per year.
EPS Next Y21.9%
EPS Next 2Y24.77%
EPS Next 3Y18.95%
EPS Next 5Y11.66%
Revenue Next Year-14.84%
Revenue Next 2Y-2.44%
Revenue Next 3Y3.14%
Revenue Next 5Y4.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKYA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as AKYA's earnings are expected to grow with 18.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.77%
EPS Next 3Y18.95%

More info and screens

0

5. Dividend

5.1 Amount

AKYA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKOYA BIOSCIENCES INC

NASDAQ:AKYA (12/23/2024, 9:35:57 AM)

2.45

-0.04 (-1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners31.53%
Inst Owner Change1.88%
Ins Owners4.04%
Ins Owner Change14.21%
Market Cap121.42M
Analysts75.71
Price Target3.57 (45.71%)
Short Float %5.84%
Short Ratio6.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.05%
Min EPS beat(2)-1.05%
Max EPS beat(2)1.15%
EPS beat(4)2
Avg EPS beat(4)-10.8%
Min EPS beat(4)-62.97%
Max EPS beat(4)19.69%
EPS beat(8)4
Avg EPS beat(8)-3.53%
EPS beat(12)4
Avg EPS beat(12)-9.73%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.51%
Min Revenue beat(2)-27.44%
Max Revenue beat(2)-3.58%
Revenue beat(4)1
Avg Revenue beat(4)-14.16%
Min Revenue beat(4)-27.44%
Max Revenue beat(4)0.3%
Revenue beat(8)5
Avg Revenue beat(8)-6.14%
Revenue beat(12)8
Avg Revenue beat(12)-2.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.41%
PT rev (3m)-30%
EPS NQ rev (1m)-3.45%
EPS NQ rev (3m)-10.09%
EPS NY rev (1m)-7.09%
EPS NY rev (3m)-7.09%
Revenue NQ rev (1m)-4.29%
Revenue NQ rev (3m)-30%
Revenue NY rev (1m)-16.54%
Revenue NY rev (3m)-16.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.4
P/FCF N/A
P/OCF N/A
P/B 8.91
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS1.75
BVpS0.28
TBVpS-0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.6%
ROE -425.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.72%
FCFM N/A
ROA(3y)-32.83%
ROA(5y)-29.39%
ROE(3y)-91.62%
ROE(5y)-89.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.54%
GM growth 5YN/A
F-Score3
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 5.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.37%
Cap/Sales 2.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.75
Quick Ratio 1.85
Altman-Z -2.36
F-Score3
WACC12.22%
ROIC/WACCN/A
Cap/Depr(3y)83.43%
Cap/Depr(5y)86.09%
Cap/Sales(3y)7.63%
Cap/Sales(5y)7.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.23%
EPS Next Y21.9%
EPS Next 2Y24.77%
EPS Next 3Y18.95%
EPS Next 5Y11.66%
Revenue 1Y (TTM)-4.99%
Revenue growth 3Y31.56%
Revenue growth 5YN/A
Sales Q2Q%-25.12%
Revenue Next Year-14.84%
Revenue Next 2Y-2.44%
Revenue Next 3Y3.14%
Revenue Next 5Y4.6%
EBIT growth 1Y32.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.74%
EBIT Next 3Y25.82%
EBIT Next 5Y15.77%
FCF growth 1Y14.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.37%
OCF growth 3YN/A
OCF growth 5YN/A